vs

Side-by-side financial comparison of EyePoint, Inc. (EYPT) and MESABI TRUST (MSB). Click either name above to swap in a different company.

EyePoint, Inc. is the larger business by last-quarter revenue ($5.3M vs $3.6M, roughly 1.5× MESABI TRUST). MESABI TRUST runs the higher net margin — 77.1% vs -1114.3%, a 1191.4% gap on every dollar of revenue. On growth, EyePoint, Inc. posted the faster year-over-year revenue change (-43.7% vs -95.5%). Over the past eight quarters, MESABI TRUST's revenue compounded faster (-24.1% CAGR vs -40.8%).

EyePoint Pharmaceuticals Inc. is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.

Mesabi Trust is a United States-based royalty trust that holds permanent royalty interests in iron ore mining properties located in Minnesota's Mesabi Range. It earns revenue primarily from royalty payments tied to the production and sale of iron ore products, with core earnings sourced from active mining partners operating on the land it holds interests in, catering to the global steel manufacturing market.

EYPT vs MSB — Head-to-Head

Bigger by revenue
EYPT
EYPT
1.5× larger
EYPT
$5.3M
$3.6M
MSB
Growing faster (revenue YoY)
EYPT
EYPT
+51.7% gap
EYPT
-43.7%
-95.5%
MSB
Higher net margin
MSB
MSB
1191.4% more per $
MSB
77.1%
-1114.3%
EYPT
Faster 2-yr revenue CAGR
MSB
MSB
Annualised
MSB
-24.1%
-40.8%
EYPT

Income Statement — Q2 FY2025 vs Q3 FY2026

Metric
EYPT
EYPT
MSB
MSB
Revenue
$5.3M
$3.6M
Net Profit
$-59.4M
$2.8M
Gross Margin
77.1%
Operating Margin
-1166.8%
Net Margin
-1114.3%
77.1%
Revenue YoY
-43.7%
-95.5%
Net Profit YoY
-92.8%
-96.5%
EPS (diluted)
$-0.85

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EYPT
EYPT
MSB
MSB
Q4 25
$3.6M
Q3 25
$5.6M
Q2 25
$5.3M
$4.7M
Q1 25
$24.5M
$6.9M
Q4 24
$11.6M
$79.0M
Q3 24
$10.5M
$6.5M
Q2 24
$9.5M
$6.3M
Q1 24
$11.7M
$6.2M
Net Profit
EYPT
EYPT
MSB
MSB
Q4 25
$2.8M
Q3 25
$4.7M
Q2 25
$-59.4M
$3.6M
Q1 25
$-45.2M
$6.1M
Q4 24
$-41.4M
$78.3M
Q3 24
$-29.4M
$5.4M
Q2 24
$-30.8M
$3.5M
Q1 24
$-29.3M
$4.7M
Gross Margin
EYPT
EYPT
MSB
MSB
Q4 25
77.1%
Q3 25
84.6%
Q2 25
76.7%
Q1 25
88.5%
Q4 24
99.1%
Q3 24
93.0%
83.2%
Q2 24
85.2%
55.7%
Q1 24
93.5%
75.3%
Operating Margin
EYPT
EYPT
MSB
MSB
Q4 25
Q3 25
Q2 25
-1166.8%
Q1 25
-199.7%
Q4 24
-390.4%
Q3 24
-311.2%
Q2 24
-364.5%
Q1 24
-285.2%
Net Margin
EYPT
EYPT
MSB
MSB
Q4 25
77.1%
Q3 25
84.6%
Q2 25
-1114.3%
76.7%
Q1 25
-184.8%
88.5%
Q4 24
-357.3%
99.1%
Q3 24
-279.0%
83.2%
Q2 24
-325.3%
55.7%
Q1 24
-250.6%
75.3%
EPS (diluted)
EYPT
EYPT
MSB
MSB
Q4 25
Q3 25
Q2 25
$-0.85
Q1 25
$-0.65
Q4 24
$-0.65
Q3 24
$-0.54
Q2 24
$-0.58
Q1 24
$-0.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EYPT
EYPT
MSB
MSB
Cash + ST InvestmentsLiquidity on hand
$255.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$246.0M
$21.1M
Total Assets
$301.1M
$26.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EYPT
EYPT
MSB
MSB
Q4 25
Q3 25
Q2 25
$255.7M
Q1 25
$318.2M
Q4 24
$370.9M
Q3 24
$253.8M
Q2 24
$280.2M
Q1 24
$299.3M
Stockholders' Equity
EYPT
EYPT
MSB
MSB
Q4 25
$21.1M
Q3 25
$22.8M
Q2 25
$246.0M
$19.6M
Q1 25
$298.4M
$23.3M
Q4 24
$336.5M
$95.3M
Q3 24
$218.7M
$22.1M
Q2 24
$228.3M
$20.7M
Q1 24
$249.9M
$21.0M
Total Assets
EYPT
EYPT
MSB
MSB
Q4 25
$26.0M
Q3 25
$24.8M
Q2 25
$301.1M
$27.4M
Q1 25
$362.6M
$101.7M
Q4 24
$418.5M
$100.7M
Q3 24
$300.9M
$26.2M
Q2 24
$324.2M
$25.1M
Q1 24
$329.2M
$26.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EYPT
EYPT
MSB
MSB
Operating Cash FlowLast quarter
$-62.6M
$3.5M
Free Cash FlowOCF − Capex
$-63.8M
FCF MarginFCF / Revenue
-1196.5%
Capex IntensityCapex / Revenue
22.9%
Cash ConversionOCF / Net Profit
1.27×
TTM Free Cash FlowTrailing 4 quarters
$-194.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EYPT
EYPT
MSB
MSB
Q4 25
$3.5M
Q3 25
$4.4M
Q2 25
$-62.6M
$2.1M
Q1 25
$-53.1M
$93.9M
Q4 24
$-35.8M
$78.2M
Q3 24
$-39.0M
$3.8M
Q2 24
$-20.2M
$2.5M
Q1 24
$-31.2M
$14.6M
Free Cash Flow
EYPT
EYPT
MSB
MSB
Q4 25
Q3 25
Q2 25
$-63.8M
Q1 25
$-53.4M
Q4 24
$-36.2M
Q3 24
$-40.6M
Q2 24
$-21.1M
Q1 24
$-32.4M
FCF Margin
EYPT
EYPT
MSB
MSB
Q4 25
Q3 25
Q2 25
-1196.5%
Q1 25
-218.4%
Q4 24
-312.7%
Q3 24
-385.8%
Q2 24
-222.4%
Q1 24
-277.0%
Capex Intensity
EYPT
EYPT
MSB
MSB
Q4 25
Q3 25
Q2 25
22.9%
Q1 25
1.1%
Q4 24
3.3%
Q3 24
15.0%
Q2 24
9.5%
Q1 24
10.2%
Cash Conversion
EYPT
EYPT
MSB
MSB
Q4 25
1.27×
Q3 25
0.92×
Q2 25
0.57×
Q1 25
15.48×
Q4 24
1.00×
Q3 24
0.71×
Q2 24
0.72×
Q1 24
3.11×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons